Development of an Oral Amphotericin B Formulation as an Alternative Approach to Parenteral Amphotericin B Administration in the Treatment of Blood-Borne Fungal Infections.

Development of an Oral Amphotericin B Formulation as an Alternative Approach to Parenteral Amphotericin B Administration in the Treatment of Blood-Borne Fungal Infections. Curr Pharm Des. 2020 Mar 11;: Authors: Wasan K Abstract In the Fall of 1999 we presented at medical "Grand Rounds" to a number of Infectious Diseases physicians at Vancouver General Hospital about the co-administration of several antifungal agents in the treatment of systemic fungal infections to patients whom were immunocompromised (i.e. cancer patients, patients waiting organ transplantation, HIV/AIDs patients etc.). During the presentation a physician from the back of room called out "can you develop an oral formulation of amphotericin B which could be effective and not have the side-effects associated with the parenteral formulations of the drug". The physician stated that an oral formulation would be a big step forward, improving patient compliance, help in pre-treatment without having to admit patients into the hospital prior to organ transplantation and be cost-effective. Initially, I responded to the physician, that it would not be possible to develop an oral amphotericin B formulation that could be absorbed from the gastrointestinal (GI) tract in a high enough concentration to be effective in treating blood-borne fungal infections and yet remain non-toxic due to the physical chemical properties of the drug. However, as I travelled back to my lab from the m...
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Tags: Curr Pharm Des Source Type: research